...We Welcome You to the Zenith Epigenetics Hub withIn The AGORACOM COMMUNITY!

Zenith's BET Inhibitor ZEN-3694 is Currently Being Evaluated in Multiple Oncology Clinical Trials

Free
Message: Re: Additional Exempt Distribution- 2023-03-31

At this point I would take any large enough BP deal being a CVR or partnership deal or buyout that allows retail shareholders some sort of liquidity A BP deal will also legitimizes Zen3684 Epigenetics science/technology. Bird in hand versus 2 in bush anology, who knows what can happen in 2 years or longer  
As for the unsecured promissory notes , I guess that what you get when insiders get advantages us minions don't get. 

Share
New Message
Please login to post a reply